Lataa...
Clinical Use of DPP-4 Inhibitors
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk. Their efficacy potential to lower HbA1c is in the range between 0.5 and...
Tallennettuna:
| Julkaisussa: | Front Endocrinol (Lausanne) |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6593043/ https://ncbi.nlm.nih.gov/pubmed/31275246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00389 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|